The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis
The Impacts of Gluten Free Diet on Disease Activity, Quality of Life and Intestinal Permeability in Patients Diagnosed With Ankylosing Spondylitis.
1 other identifier
interventional
60
1 country
4
Brief Summary
Subclinical intestinal inflammation and intestinal permeability have been reported in patients with ankylosing spondylitis. Gluten is one of the main triggers of zonulin releaseand gluten intake may contribute to the development of the disease by increasing intestinal permeability. This study aims to determine the impacts of a gluten-freediet on intestinal permeability, sub-clinical intestinal inflammation, disease activity, functional status and quality of life in patients with ankylosing spondylitis. The main questions it aims to answer are: Does a gluten-free diet have an effect on disease activity and functional status in patients with ankylosing spondylitis? Does a gluten-free diet have an effect on intestinal permeability and subclinical intestinal inflammation in patients with ankylosing spondylitis? The investigators will evaluate the effects of the gluten-free diet compared to a control group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2025
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 31, 2025
CompletedFirst Submitted
Initial submission to the registry
August 26, 2025
CompletedFirst Posted
Study publicly available on registry
September 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
ExpectedSeptember 10, 2025
September 1, 2025
11 months
August 26, 2025
September 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
effects of a 8-week Gluten Free Diet versus placebo diet on fasting serum zonulin levels
Serum zonulin will be evaluated as a biomarker of intestinal permeability. It will be measured by ELISA(enzyme-linked immunosorbent assay) method.
Change from baseline serum zonulin at 8 weeks
effects of a 8-week Gluten Free Diet versus placebo diet on fasting serum LPS levels
Serum LPS will be evaluated as a biomarker of intestinal permeability. It will be measured by ELISA(enzyme-linked immunosorbent assay) method.
Change from baseline serum LPS at 8 weeks
Secondary Outcomes (15)
effects of a 8 week Gluten Free Diet versus placebo diet on the activity of Ankylosing Spondylitis evaluated by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Change from baseline BASDAI score at 8 weeks
effects of a 8-week Gluten Free Diet versus placebo diet on functional disability asssessed by Bath Ankylosing Spondylitis Functionnal Index (BASFI) questionnaire
Change from baseline BASFI score at 8 weeks
effects of a 8 week Gluten Free Diet versus placebo diet on the quality of life of Ankylosing Spondylitis evaluated by the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).
Change from baseline ASQoL score at 8 weeks
effects of a 8-week Gluten Free Diet versus placebo diet on CRP levels
Change from baseline CRP at 8 weeks
effects of a 8-week Gluten Free Diet versus placebo diet on ESR levels
Change from baseline ESR at 8 weeks
- +10 more secondary outcomes
Study Arms (2)
Control Group
NO INTERVENTIONIn the control arm, patients will continue their eating habits.
Gluten Free Diet
EXPERIMENTALPatients in the experimental arm will received a gluten-free diet for 8 weeks.
Interventions
Patients in the experimental arm will received a gluten-free diet for 8 weeks.
Eligibility Criteria
You may qualify if:
- diagnosis of axial SpA defined by ASAS criteria
- Adults (aged 18-64 years)
- stable treatment (NSAID and/or DMARD) for at least 3 months
- provide written informed consent and submit to the requirements of the study
You may not qualify if:
- have a history of celiac disease;
- have a history of Ulcerative Colitis, Crohn's Disease and Irritable Bowel Syndrom
- patients with Type 1 and Type 2 Diabetes Mellitus
- patients with Hashimoto Thyroiditis
- are pregnant, breastfeeding,
- patients who have used omega-3 and vitamins (A, C, E) regularly in the last 3 months.
- BMI \<18,50 kg/m2
- BMI ≥29,99 kg/m2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Bakırköy Dr. Sadi Konuk Training and Research hospital
Istanbul, Turkey (Türkiye)
İstanbul Medeniyet University
Istanbul, Turkey (Türkiye)
İstanbul Sağlık Bilimleri University
Istanbul, Turkey (Türkiye)
Marmara University
Istanbul, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dietitian
Study Record Dates
First Submitted
August 26, 2025
First Posted
September 10, 2025
Study Start
January 31, 2025
Primary Completion
December 30, 2025
Study Completion (Estimated)
May 31, 2026
Last Updated
September 10, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share